Shorter Surgery Gap, Better Outcomes: New Insights into Immunochemotherapy for Esophageal Cancer A Look into New Treatment Strategies for a Difficult Disease Esophageal cancer (EC) is among the most aggressive and deadly cancers worldwide. It […]
Peer review is crucial in the scientific publishing process, as it ensures that research papers meet high-quality and accurate standards. Each month, the BiomolBiomed Editorial team recognizes a reviewer who has delivered outstanding and constructive […]
Lung cancer is the leading cause of cancer-related deaths globally, with nearly 2.5 million new cases annually. Non-small cell lung cancer (NSCLC) accounts for approximately 80%–85% of all lung cancer cases. Most patients are diagnosed […]
Low-grade glioma (LGG) belongs to a large class of gliomas, tumors that occur in the brain and spinal cord, with great intrinsic heterogeneity. In recent years, in-depth studies of the tumor microenvironment have made a […]
Colorectal cancer is the 3rd most common cancer worldwide. Immunotherapy has been shown to be therapeutically effective in patients with colorectal cancer who have significant levels of microsatellite instability (regions of repeated DNA that change […]
Le et al. recently reported (Science 10.1126/science.aan6733 (2017); (ClinicalTrials.gov number, NCT01876511) on the success of immune checkpoint blockade with anti-PD-1 antibodies in the patients whose cancers exhibited microsatellite instability-high (MSI-H) status. The study included 12 […]
Targeted therapy based on the immune checkpoint inhibitors (Anti-PD1/PD-L1) has revolutionized cancer treatment and outcome of several solid and hematologic malignancies, including non-small cell lung carcinoma (NSCLC), metastatic renal cell carcinoma, metastatic malignant melanoma, advanced/metastatic […]
Copyright (c) 2021 Association of Basic Medical Sciences of FBIH